1874. Tdap Vaccination Rates in Pregnant Women at UCLA: Impact of In-Office Vaccine Availability
Session: Poster Abstract Session: Vaccines: Pertussis
Saturday, October 10, 2015
Room: Poster Hall
  • Beni_Lees_Johnson_Cherry_Poster_upload_final.png (779.1 kB)
  • Background:

    Nearly all deaths from pertussis occur in the first 3 months of life; Tetanus-Diphtheria-Pertussis (Tdap) immunization in pregnant women will prevent most of these deaths. In October 2011 the Advisory Committee on Immunization Practices (ACIP) recommended that Tdap be given to all pregnant women. As of October 2013 only 25% of pregnant women in California had received Tdap. In July 2014, the UCLA Health System made Tdap vaccine available in all UCLA OB practices. Our study aimed to measure the vaccination rate in pregnant women, to analyze why eligible women did not receive the vaccine, and to determine if in-office vaccine availability had an impact on vaccination rates.


    This study was a retrospective chart review of women who delivered between April and December 2014 at either Ronald Reagan Medical Center or Santa Monica Medical Center. Data collected included discussion of the vaccine, vaccine administration, gestational age at administration, and reason for lack of administration. Vaccination rates were analyzed by gestational age at administration to assess compliance with CDC guidelines, and by date to determine the impact of in-office vaccine availability.


    The records of 624 patients were analyzed. Of the records reviewed, 48 of the patients received their care before July 2014; the remaining 576 patients received their care between August and December 2014. Of this group, 503 received their care from UCLA providers and 73 received their care from non-UCLA providers. Vaccination and discussion rates are presented in Figure 1. Overall, 77% of patients from UCLA providers received the Tdap vaccine, compared to 21% in patients of non-UCLA providers. Amongst the 23% of unvaccinated UCLA patients, 14% had no documented discussion with their provider, while 9% declined vaccination after discussion. Discussion rates improved linearly from 65% in April to 92% in December. Vaccination rates improved from 55% in April to 77% in December, with a discrete jump of 20% in July.


    In-office availability of the Tdap vaccine greatly improves vaccination rates in pregnant women.

    Figure 1: Vaccination and discussion rates from April 2014 to December 2014.

    Catherine Beni, Medical Student1, Andrew Lees, Medical Student1, Michael Johnson, MD2 and James D. Cherry, MD, MSc, FIDSA3, (1)University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, (2)Obstetrics and Gynecology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, (3)Pediatric Infectious Diseases, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA


    C. Beni, None

    A. Lees, None

    M. Johnson, None

    J. D. Cherry, Global Pertussis Initiative: Member , Honoraria for participating and speaking at many GPI meetings since 2000
    Sanofipasteur: Speaker's Bureau , Speaker honorarium

    See more of: Vaccines: Pertussis
    See more of: Poster Abstract Session
    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.